Moderna stock slips 3.07% as raised outlook faces execution test
Published on 11/12/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSModerna's recovery faces its next test
- Third-quarter revenue grew 29 percent to 1.3 billion US dollars.
- Management raised 2026 revenue-growth guidance to 15 percent to 25 percent from up to 10 percent previously.
- Vaccine demand, cost discipline and pipeline execution remain central to the recovery case.
Moderna reported a return to quarterly profitability and raised its full-year revenue outlook on November 6, according to Moderna Investor Relations. The company said third-quarter revenue grew 29 percent to 1.3 billion US dollars and that it was profitable.
Moderna stock traded at 215.18 euros on Lang & Schwarz at 16:38 CET on Thursday, November 12, 2026, 3.07 percent below the Xetra close of Wednesday, November 11. Yahoo Finance lists the Xetra close at 222.00 euros.
Higher guidance raises the bar
Management now expects 2026 revenue to grow 15 percent to 25 percent, compared with its previous expectation of up to 10 percent. Moderna also lifted its expected year-end cash and investments to 8.1 billion to 8.3 billion US dollars from 4.7 billion to 5.2 billion US dollars.
The improved outlook reflects stronger operating execution and higher vaccine demand, while cash costs declined 10 percent to 1.0 billion US dollars in the third quarter. The company said the raised framework would mark its first year of revenue growth since 2022.
Pipeline progress meets execution risk
Moderna highlighted positive Phase 3 results for intismeran, its individualized cancer therapy developed with Merck, in resected high-risk melanoma. The company also received US approval for mFLUSIVA, its seasonal influenza vaccine and fifth approved product globally.
Those milestones broaden Moderna's commercial and development base, but future results still depend on vaccine demand, regulatory progress and the conversion of clinical assets into recurring revenue. The higher cash outlook gives the company more flexibility, while development spending and future financing remain relevant to profitability and dilution.
The S&P 500 sets the broader US equity-market backdrop for Moderna investors.
More news and analyses on Moderna stock
Moderna Inc. key figures
- Company: Moderna Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Home exchange: Nasdaq
- Lang & Schwarz price: 215.18 euros at 16:38 CET on November 12, 2026
- Change versus Xetra close: -3.07 percent versus 222.00 euros on November 11, 2026
- Third-quarter revenue: 1.3 billion US dollars
- 2026 revenue outlook: 15 percent to 25 percent growth
